Evidence map›Paper›PMID 14514569›Full record

Trial reportDiabetes care2003

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

Anthony Keech, David Colquhoun, James Best, Adrienne Kirby, R John Simes, David Hunt, Wendy Hague, Elaine Beller, Manjula Arulchelvam, Jennifer Baker and 2 more

Registry-linked trialOpen access · bronzeAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes care, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02470455 (Effect of Atorvastatin on Glycemic Control in Prediabetic Patients), which is not on this map. Cited by 93 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 10 pooled it
23.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02470455 completedstarted 2011, after this paper: background citation

Effect of Atorvastatin on Glycemic Control in Prediabetic Patients

Ran2011Enrolled75Registered outcomes4Posted comparisons0ConditionsPrediabetic StateArmsAtorvastatin
PMID 18191683PMID 11157685PMID 20167359PMID 12573493PMID 17317382PMID 15031036other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 10 syntheses or guidelines pooled it, 313 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Diabetes: managing dyslipidaemia.BMJ clinical evidence · 2008
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. The CARDS trial: diabetic patients dealt a winning hand.Current atherosclerosis reports · 2006
    Trial
  18. Trial
  19. Trial
  20. Trial

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Anthony KeechNational Health Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia. enquiry@ctc.usyd.edu.au
David Colquhoun
James Best
Adrienne Kirby
R John Simes
David Hunt
Wendy Hague
Elaine Beller
Manjula Arulchelvam
Jennifer Baker
Andrew Tonkin
LIPID Study Group
National Health and Medical Research Council · AUUniversity of Sydney · AUNational Heart Foundation of Australia · AUSt Vincent's Hospital · AUThe Royal Melbourne Hospital · AUWesley Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDiabetes, a major health problem worldwide, increases the risk of cardiovascular disease and its associated mortality: The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that cholesterol-lowering treatment with pravastatin reduced mortality and coronary heart disease (CHD) events in 9014 patients aged 31-75 years with CHD and total cholesterol 4.0-7.0 mmol/l. We measured the effects of pravastatin therapy, 40 mg/day over 6.0 years, on the risk of CHD death or nonfatal myocardial infarction and other cardiovascular outcomes in 1,077 LIPID patients with diabetes and 940 patients with impaired fasting glucose (IFG).

resultsIn patients allocated to placebo, the risk of a major CHD event was 61% higher in patients with diabetes and 23% higher in the IFG group than in patients with normal fasting glucose, and the risk of any cardiovascular event was 37% higher in the diabetic group and 19% higher in the IFG group. Pravastatin therapy reduced the risk of a major CHD event overall from 15.9 to 12.3% (relative risk reduction [RRR] 24%, P < 0.001) and from 23.4 to 19.6% in the diabetic group (19%, P = 0.11); in the diabetic group, the reduction was not significantly different from the reductions in the other groups. Pravastatin reduced the risk of any cardiovascular event from 52.7 to 45.2% (21%, P < 0.008) in patients with diabetes and from 45.7 to 37.1% (26%, P = 0.003) in the IFG group. Pravastatin reduced the risk of stroke from 9.9 to 6.3% in the diabetic group (RRR 39%, CI 7-61%, P = 0.02) and from 5.4 to 3.4% in the IFG group (RRR 42%, CI -9 to 69%, P = 0.09). Pravastatin did not reduce the incidence of diabetes. Over 6 years, pravastatin therapy prevented one major CHD event (CHD death or nonfatal myocardial infarction) in 23 patients with IFG and 18 patients with diabetes. A meta-analysis of other major trials confirmed the high absolute risks of diabetes and IFG and the absolute benefits of statin therapy in these patients.

conclusionsCholesterol-lowering treatment with pravastatin therapy prevents cardiovascular events, including stroke, in patients with diabetes or IFG and established CHD.

Indexed as

AdultAgedAngina, UnstableAnticholesteremic AgentsBlood GlucoseCardiovascular DiseasesCoronary Artery DiseaseCoronary RestenosisDiabetes Mellitus, Type 2FastingFemaleFollow-Up StudiesGlucose IntoleranceHumansHyperlipidemiasMaleAnticholesteremic AgentsBlood GlucosePravastatin

Identifiers

PMID14514569
OpenAlexW2086139919

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.